Viking Therapeutics Inc. has detailed its latest advancements in the development of novel therapeutics for metabolic and endocrine diseases. The company highlighted its clinical programs, including VK2735, a dual GLP-1/GIP agonist for obesity, which successfully achieved its primary endpoint in the VENTURE Phase 2 obesity study, with a Phase 3 study planned for the second quarter of 2025. Additionally, the VK2735 oral version has completed Phase 2 enrollment after demonstrating positive proof of concept and weight reduction in Phase 1. For NASH/MASH, VK2809, a selective thyroid receptor-β agonist, successfully completed the VOYAGE Phase 2b trial, meeting primary and secondary endpoints. In the rare disease domain, VK0214, another thyroid receptor-β agonist, showed proof of concept in reducing key biomarkers in X-ALD patients during Phase 1b studies. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。